Tumor-associated antigens from heterogeneous tumor cell lysate (TCL)

Tumor-associated antigens from heterogeneous tumor cell lysate represent a complex mixture of proteins, lipids, and carbohydrates derived from the disruption of cancer cells to serve as a polyvalent antigenic source (Frontiers in Immunology, 2020). This mixture includes both shared tumor-associated antigens (TAAs) and patient-specific neoantigens, which helps the immune system address intra-tumoral heterogeneity and reduces the risk of antigen escape (Journal of Hematology & Oncology, 2013). These lysates are primarily utilized in the production of personalized cancer vaccines, where they are used to pulse dendritic cells ex vivo or are administered directly with potent adjuvants (Nature Reviews Cancer, 2004). Once introduced, the antigens are processed by antigen-presenting cells and presented via MHC pathways to prime a broad repertoire of CD4+ and CD8+ T cells (Vaccines, 2021). The therapeutic goal is to induce a robust, polyclonal cytotoxic T-lymphocyte response capable of recognizing and eliminating diverse populations of tumor cells (Northwest Biotherapeutics, 2023). This approach is particularly relevant for treating highly heterogeneous and aggressive malignancies such as glioblastoma multiforme, melanoma, and renal cell carcinoma (Clinical Cancer Research, 2015). While generally considered safe, potential challenges include the risk of inducing autoimmune cross-reactivity against normal tissues and the logistical complexity of preparing autologous lysates (Cancer Immunology, Immunotherapy, 2018). Clinical efficacy is often monitored through biomarkers such as delayed-type hypersensitivity responses and interferon-gamma production by T cells (Journal of Clinical Oncology, 2011).

Other names

Whole tumor cell lysateAutologous tumor lysateAllogeneic tumor lysatePolyvalent tumor-associated antigensTumor cell lysate-derived antigens

Induction of a polyclonal immune response through the presentation of multiple tumor-associated antigens and neoantigens to T cells via MHC Class I and II pathways (Frontiers in Immunology, 2020).